摘要:2025年美国临床肿瘤学会胃肠道肿瘤研讨会(ASCO GI)将于1月23日至25日在美国加利福尼亚州旧金山举行,旨在为世界肿瘤学者传递国际消化肿瘤领域的最新研究进展。目前大会官网已披露了摘要标题,大会第三日聚焦结直肠癌领域,多项中国研究入选,医脉通特此整理相关
前言
2025年美国临床肿瘤学会胃肠道肿瘤研讨会(ASCO GI)将于1月23日至25日在美国加利福尼亚州旧金山举行,旨在为世界肿瘤学者传递国际消化肿瘤领域的最新研究进展。目前大会官网已披露了摘要标题,大会第三日聚焦结直肠癌领域,多项中国研究入选,医脉通特此整理相关摘要标题,让我们先睹为快。
Poster session
01
摘要号:56
Survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis.
讲者:Hsiang-Lin Tsai 高雄医学大学
02
摘要号:57
Effectiveness of anti-epidermal growth factor receptor agents in elderly patients (age ≥ 70 years) with RAS wild-type metastatic colorectal cancer: Nationwide real-world data.
讲者:Chao-Yuan Wang 高雄医学大学附设中和纪念医院
03
摘要号:68
Vascular endothelial growth factor receptor (VEGFR) -tyrosine kinase inhibitors combined with programmed death receptor-1 (PD-1) inhibitors as third- or later-line treatment in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): A retrospective study.
讲者:Xiaoqian Li 山东省肿瘤医院
04
摘要号:77
Bevacizumab plus mFOLFOX6/FOLFIRI sequential bevacizumab plus capecitabine maintenance in RAS-mutated advanced colorectal cancer: A real-world study of first-line/second-line conversion therapy.
讲者:Ying Yan 中国科学技术大学附属第一医院
05
摘要号:133
Total neoadjuvant therapy with FOLFOX plus bevacizumab and short-course radiotherapy for Ras mutant, high-risk, locally advanced rectal cancer: The TRAINER trial.
讲者:Jingyi Liu 上海交通大学医学院附属瑞金医院
06
摘要号:145
Updated analysis of a phase 2 study of fruquintinib plus trifluridine/tipiracil (TAS-102) as third-line treatment in patients with metastatic colorectal adenocarcinoma.
讲者:彭建军 中山大学附属第一医院
07
摘要号:150
Short-course radiotherapy-based total neoadjuvant therapy combined with tislelizumab in the treatment of locally advanced rectal cancer (Neo-STAR): Early outcomes of a prospective, randomized phase II trial.
讲者:吴凤鹏 河北医科大学第四医院
08
摘要号:151
Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.
讲者:Yun Xu 复旦大学附属肿瘤医院
09
摘要号:155
Phase II study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second‐line therapy for patients with metastatic colorectal cancer.
讲者:Wenwei Yang 中国医学科学院肿瘤医院
10
摘要号:157
Prognosis of patients with liver single-organ metastases: Updated survival results of BBCAPX-II.
讲者:袁瑛 浙江大学医学院附属第二医院
11
摘要号:166
Efficacy and safety of fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study.
讲者:廖旺军 南方医科大学南方医院
12
摘要号:167
Updated survival results of ZL-IRIAN: Irinotecan plus anlotinib or in combination with penpulimab as second-line treatment of metastatic colorectal cancer.
讲者:王辰辰 复旦大学附属肿瘤医院
13
摘要号:170
Updated efficacy and subgroup analysis of first-line serplulimab plus bevacizumab and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.
讲者:徐瑞华 中山大学肿瘤防治中心
14
摘要号:174
Exploratory study of TAS-102 combined with intermittent administration of fruquintinib in the treatment of third-line metastatic colorectal cancer.
讲者:Jiayu Niu 中国科学技术大学附属第一医院
15
摘要号:177
OP-TNT: Phase II study of total neoadjuvant chemoradiotherapy followed by local resection for early distal rectal carcinoma.
讲者:Zhang Xian 复旦大学附属中山医院
16
摘要号:185
Neoadjuvant PD-1 blockade in mismatch repair-deficient or microsatellite instability-high, locally advanced and resectable colorectal cancer: A retrospective real-world analysis.
讲者:Yugui Lian 郑州大学第一附属医院
17
摘要号:190
QL1203 vs placebo plus mFOLFOX6 as first-line therapy in RAS wild-type, metastatic colorectal cancer (mCRC): Interim analysis (IA) of a multicenter, randomized, double-blinded, parallel, phase 3 trial.
讲者:郭伟剑 复旦大学附属肿瘤医院
18
摘要号:192
Short-course radiotherapy (SCRT) followed by fruquintinib plus adebrelimab and CAPOX in the total neoadjuvant therapy of locally advanced rectal cancer (LARC): A multicenter, single-arm, open-label, phase II study (UNION TNT).
讲者:林振宇 华中科技大学同济医学院附属协和医院
19
摘要号:194
Efficacy and safety of anlotinib as a later-line treatment for advanced colorectal cancer.
讲者:宋扬 空军军医大学唐都医院
20
摘要号:195
Liposomal irinotecan + 5-fluorouracil + leucovorin + bevacizumab as second-line therapy in metastatic colorectal cancer (IRIS): A multi-center, single-arm, prospective, phase II study.
讲者:胡旭华 河北医科大学第四医院
21
摘要号:198
Preliminary safety and efficacy of upfront FOLFOXIRI and bevacizumab with cadonilimab in patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer: A multicenter phase II study (SYLT-026).
讲者:林榕波 福建省肿瘤医院
22
摘要号:201
Neoadjuvant chemotherapy with FOLFOXIRI for high-risk relapsed locally advanced colon cancer: A single-arm phase II trial.
讲者:Yuwen Zhou 四川大学华西医院
23
摘要号:203
Real-world outcomes of targeted therapies and local interventions in BRAF V600E–mutated metastatic colorectal cancer: A single-center retrospective study.
讲者:Ziqin Lin 中山大学附属第六医院
24
摘要号:LBA210
Short-course radiation(SCRT) followed by 6 cycles of cadonilimab plus mFOLFOX6 as neoadjuvant therapy for patients with locally advanced rectal cancer (LARC): A multicenter, single arm, phase II trial (NeoCaCRT).
讲者:何婉 深圳市人民医院
25
摘要号:240
Utilization of SDC2 gene in conjunction with SEPTIN9 gene methylation analysis for the diagnosis and efficacy assessment of colorectal cancer.
讲者:Rongjia Xie 同济大学附属第十人民医院
26
摘要号:246
Effects of targeting CTMP on immunogenicity of MSI-L colon adenocarcinoma cells by metabolism and cell cycle modulation.
讲者:Cheng Gu 同济大学附属第十人民医院
27
摘要号:278
Comprehensive landscape of FGFR variations and prognosis revelance in colorectal cancer from circulating tumor DNA and tissue gene analyses in 2083 patients.
讲者:Xiaoshuang Lyu 中山大学附属第六医院
28
摘要号:292
The role and molecular mechanism of GDF5 in regulating cell migration and angiogenesis via the Hippo-YAP signaling pathway in colorectal cancer.
讲者:Peijie Lei 青岛大学附属医院
29
摘要号:298
Development and validation of a deep learning–based pathomics signature for prognosis and chemotherapy benefits in colorectal cancer: A retrospective multicenter cohort study.
讲者:Shenghan Lou 哈尔滨医科大学附属肿瘤医院
Trials in Progress Poster Session
01
摘要号:TPS314
A phase II, randomized study of JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC).
讲者:许剑民 复旦大学附属中山医院
02
摘要号:TPS315
Chemoradiotherapy (CRT) followed by sequential tislelizumab (TIS) + CAPOX and TIS monotherapy for organ preservation in locally advanced low rectal cancer.
讲者:Wentao Tang 复旦大学附属中山医院
03
摘要号:TPS316
Cetuximab and vemurafenib plus liposomal irinotecan (II), leucovorin and fluorouracil for BRAFV600E-mutated advanced colorectal cancer (IMPROVEMENT2): A multicenter, open-label, randomized controlled trial.
讲者:王湛 海军军医大学第二附属医院
备注:排名不分先后,按照摘要号进行排序
如有遗漏或任何问题,请给我们留言~
撰写:Babel
排版:Aurora
执行:Aurora
医脉通是专业的在线医生平台,“感知世界医学脉搏,助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品,全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。
本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容,不能以任何方式取代专业的医疗指导,也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的,本平台不承担相关责任。本平台对发布的内容,并不代表同意其描述和观点。若涉及版权问题,烦请权利人与我们联系,我们将尽快处理。
来源:关注心脑健康